AEON Biopharma
AEON
21 hedge funds and large institutions have $20.5M invested in AEON Biopharma in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 13 reducing their positions, and 69 closing their positions.
1.15% less ownership
Funds ownership: 1.24% → 0.1% (-1.1%)
75% less funds holding
Funds holding: 85 → 21 (-64)
85% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 13
92% less capital invested
Capital invested by funds: $248M → $20.5M (-$228M)
93% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 69
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Sandia Investment Management
Boston,
Massachusetts
|
+$1.31M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$546K |
| 3 |
Walleye Capital
New York
|
+$161K |
| 4 |
CCM
CAAS Capital Management
New York
|
+$119K |
| 5 |
FTUS
Flow Traders U.S.
New York
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$13.3M |
| 2 |
DKCM
Davidson Kempner Capital Management
New York
|
-$12.8M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$12.6M |
| 4 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
-$12.1M |
| 5 |
D.E. Shaw & Co
New York
|
-$11.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LA
76
Linden Advisors
New York
| – | -$375K | -518 | Closed |
|
|
ACA
77
Arena Capital Advisors
Los Angeles,
California
| – | -$308K | -425 | Closed |
|
|
E
78
Ergoteles
New York
| – | -$262K | -363 | Closed |
|
|
AGC
79
Angelo Gordon & Co
New York
| – | -$251K | -347 | Closed |
|
|
CCM
80
Cinctive Capital Management
New York
| – | -$251K | -347 | Closed |
|
|
RCM
81
Robinson Capital Management
Grosse Pointe Farms,
Michigan
| – | -$248K | -342 | Closed |
|
|
TI
82
Tidal Investments
Milwaukee,
Wisconsin
| – | -$248K | -342 | Closed |
|
|
KKRC
83
Kohlberg Kravis Roberts & Co
New York
| – | -$223K | -308 | Closed |
|
|
LCM
84
Landscape Capital Management
Englewood,
New Jersey
| – | -$207K | -287 | Closed |
|
|
TAM
85
Terrapin Asset Management
Miami,
Florida
| – | -$201K | -278 | Closed |
|
|
AA
86
Ancora Advisors
Cleveland,
Ohio
| – | -$169K | -233 | Closed |
|
|
6CM
87
683 Capital Management
New York
| – | -$101K | -139 | Closed |
|
88
BlackRock
New York
| – | -$101K | -139 | Closed |
|
|
FC
89
Foursixthree Capital
New York
| – | -$101K | -139 | Closed |
|
90
UBS Group
Zurich,
Switzerland
| – | -$8.06K | -11 | Closed |
|
AEON Hedge Fund Activity: Q1 2023 in Review
21 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2023, worth a combined $20.5M — down 92% from $248M a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of AEON and 5 opened new positions — a net loss of 64 holders — while 13 trimmed existing stakes and 2 added.
The largest buyer was Sandia Investment Management, opening a new position worth an estimated $1.31M. The largest seller was Marshall Wace, exiting entirely with an estimated $13.3M sold.
- 21 institutional investors held AEON Biopharma (AEON) as of Q1 2023, down from 85 in Q4 2022.
- Funds reported $20.5M of AEON Biopharma stock for Q1 2023, down 92% quarter-over-quarter.
- 5 funds opened new AEON Biopharma positions in Q1 2023 and 69 closed out, a net change of -64 holders.
- The largest AEON Biopharma buyer in Q1 2023 was Sandia Investment Management, an estimated $1.31M added.
- The largest AEON Biopharma seller in Q1 2023 was Marshall Wace, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2023.